Treatments / ASMQ (Malaria)

ASMQ (Malaria)


ASMQ to treat Malaria Fixed dose combination of Artesunate + Mefloquine
First new malaria treatment made in Latin America, for Latin America and South East Asia!
Launched in 2008 Developed by an innovative collaboration between DNDi, Brazil and South-East Asia within the FACT Project Consortium Produced by Farmanguinhos/Fiocruz (Brazilian public pharmaceutical company) The 2-in-1 combination ensures that both drugs are taken together in correct proportions Simple and Adapted Regimen for Children and Adults. As Easy as 1-2-3! Adapted Packaging: 3 years shelf life: the longest shelf life of any FDC for malaria. High compliance and low risk of resistance WHO Prequalification in September 2012 Registered in Brazil in 2008, in India in 2011, in Malaysia and Myanmar in 2012 Successful South-South technology transfer from Farmanguinhos to Cipla Ltd, India Admission of Farmanguinhos/Fiocruz to the PAHO Strategic Fund in April 2013 will allow procurement by South American national control programs Soon available in other countries in Latin America and Southeast Asia Download ASMQ brochure, September 2012 [1.9MB] Download ASMQ scientific document, September 2012 [1.3MB] Download ASMQ press pack, April 2008 [1.1MB] Read more about ASMQ project		ASMQ News
		Implementation progress ASMQ: WHO Prequalified in September 2012! ASMQ registered in Malaysia and Myanmar! Farmanguinhos/Fiocruz admitted to PAHO Strategic Fund 100'000 treatments distributed
		Recent Scientific Publications Malaria Journal, February 2013 The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study
		Recent Events 1 December 2011 ASMQ Workshop in the frame of DNDi Partners' Meeting, Rio, Brazil

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License